Literature DB >> 19671857

Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells.

Tsutomu Iwasa1, Isamu Okamoto, Minoru Suzuki, Erina Hatashita, Yuki Yamada, Masahiro Fukuoka, Koji Ono, Kazuhiko Nakagawa.   

Abstract

PURPOSE: Therapeutic strategies that target the insulin-like growth factor I receptor (IGF-1R) hold promise for a wide variety of cancers. We have now investigated the effect of CP-751,871, a fully human monoclonal antibody specific for IGF-IR, on the sensitivity of human non-small cell lung cancer (NSCLC) cell lines to radiation. EXPERIMENTAL
DESIGN: The radiosensitizing effect of CP-751,871 was evaluated on the basis of cell death, clonogenic survival, and progression of tumor xenografts. Radiation-induced damage was evaluated by immunofluorescence analysis of the histone gamma-H2AX and Rad51.
RESULTS: A clonogenic survival assay revealed that CP-751,871 increased the sensitivity of NSCLC cells to radiation in vitro. CP-751,871 inhibited radiation-induced IGF-IR signaling, and potentiated the radiation-induced increases both in the number of apoptotic cells and in the activity of caspase-3. Immunofluorescence analysis of the histone gamma-H2AX and Rad51 also showed that CP-751,871 inhibited the repair of radiation-induced DNA double-strand breaks. Finally, combination therapy with CP-751,871 and radiation delayed the growth of NSCLC tumor xenografts in nude mice to a greater extent than did either treatment modality alone.
CONCLUSIONS: These results show that CP-751,871 sensitizes NSCLC cells to radiation both in vitro and in vivo, and that this effect of CP-751,871 is likely attributable to the inhibition of DNA repair and enhancement of apoptosis that result from attenuation of IGF-IR signaling. Combined treatment with CP-751,871 and radiation thus warrants further investigation in clinical trials as a potential anticancer strategy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19671857     DOI: 10.1158/1078-0432.CCR-09-0478

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  23 in total

Review 1.  Targeted therapy in bone and soft tissue sarcoma in children and adolescents.

Authors:  Patrick A Thompson; Murali Chintagumpala
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

Review 2.  The insulin-like growth factor system in cancer.

Authors:  S John Weroha; Paul Haluska
Journal:  Endocrinol Metab Clin North Am       Date:  2012-06       Impact factor: 4.741

Review 3.  Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh.

Authors:  Joel W Neal; Lecia V Sequist
Journal:  Curr Treat Options Oncol       Date:  2010-06

4.  Insulin-like growth factor-1 receptor knockdown enhances radiosensitivity via the HIF-1α pathway and attenuates ATM/H2AX/53BP1 DNA repair activation in human lung squamous carcinoma cells.

Authors:  Xiaoxing Liu; Haiyan Chen; Xin Xu; Ming Ye; Hongbin Cao; Lei Xu; Yanli Hou; Jianmin Tang; Di Zhou; Yongrui Bai; Xiumei Ma
Journal:  Oncol Lett       Date:  2018-05-11       Impact factor: 2.967

Review 5.  Implications of Insulin-like Growth Factor 1 Receptor Activation in Lung Cancer.

Authors:  Fariz Nurwidya; Sita Andarini; Fumiyuki Takahashi; Elisna Syahruddin; Kazuhisa Takahashi
Journal:  Malays J Med Sci       Date:  2016-05

6.  Role of IGF-1 receptor in radiation response.

Authors:  Almudena Valenciano; Luis Alberto Henríquez-Hernández; Mercedes Moreno; Marta Lloret; Pedro Carlos Lara
Journal:  Transl Oncol       Date:  2012-02-01       Impact factor: 4.243

7.  Establishment of platform for screening insulin-like growth factor-1 receptor inhibitors and evaluation of novel inhibitors.

Authors:  Lin-jiang Tong; Hua Xie; Ting Peng; Xiao-feng Liu; Xian-liang Xin; Xun Huang; Si-meng Chen; Hong-yan Liu; Hong-lin Li; Mei-yu Geng; Ming Yin; Jian Ding
Journal:  Acta Pharmacol Sin       Date:  2011-06-06       Impact factor: 6.150

Review 8.  DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity.

Authors:  Henning Willers; Liliana Gheorghiu; Qi Liu; Jason A Efstathiou; Lori J Wirth; Mechthild Krause; Cläre von Neubeck
Journal:  Semin Radiat Oncol       Date:  2015-05-14       Impact factor: 5.934

9.  Ewing's sarcoma: overcoming the therapeutic plateau.

Authors:  Vivek Subbiah; Razelle Kurzrock
Journal:  Discov Med       Date:  2012-06       Impact factor: 2.970

10.  A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by [(18)F]fluorothymidine-positron emission tomography.

Authors:  Seung Jin Lee; Eun Jung Kim; Haeng Jung Lee; Seog Young Kim; Seung Jun Oh; Jin Sook Ryu; Dae Hyuk Moon; Jin-Hee Ahn; Sang-We Kim
Journal:  Invest New Drugs       Date:  2012-09-18       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.